Teriflunomide
- Generic Name
- Teriflunomide
- Brand Names
- Aubagio, Teriflunomide Accord, Teriflunomide Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C12H9F3N2O2
- CAS Number
- 163451-81-8
- Unique Ingredient Identifier
- 1C058IKG3B
- Background
Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of hepatoxicity and teratogenicity for patients using teriflunomide.
- Indication
Used in the treatment of relapsing forms of multiple sclerosis (MS).
- Associated Conditions
- Multiple Sclerosis
Examining the Risk of Skin Cancer in Multiple Sclerosis Patients Using Fingolimod: a Population-Based Study
- Conditions
- Multiple SclerosisSkin CancerSkin Cancer MelanomaSkin Cancers - Basal Cell CarcinomaSkin Cancer, Squamous CellMultiple Sclerosis (MS) - Relapsing-remitting
- Interventions
- First Posted Date
- 2024-11-26
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- University of British Columbia
- Target Recruit Count
- 4000
- Registration Number
- NCT06705608
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
- Conditions
- Relapsing Multiple SclerosisSecondary Progressive Multiple SclerosisProgressive Relapsing Multiple Sclerosis
- Interventions
- First Posted Date
- 2024-04-17
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 2500
- Registration Number
- NCT06372145
- Locations
- 🇨🇿
Investigational Site Number : 2030008, Prague, Czechia
🇨🇿Investigational Site Number : 2039906, Prague, Czechia
🇨🇿Investigational Site Number : 2039905, Prague, Czechia
Teriflunomide for Steroid-resistant/Relapse Immune Thrombocytopenia
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT06190145
- Locations
- 🇨🇳
Peking University Insititute of Hematology, Peking University People's Hospital, Beijing, China
The Combination of Teriflunomide and Danazol for Steroid-resistant/Relapse Immune Thrombocytopenia
- First Posted Date
- 2023-12-20
- Last Posted Date
- 2023-12-20
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 124
- Registration Number
- NCT06176911
- Locations
- 🇨🇳
Peking University Insititute of Hematology, Peking University People's Hospital, Beijing, Beijing, China
Teriflunomide Plus High-dose Dexamethasone as First-line Treatment in Newly Diagnosed Primary Immune Thrombocytopenia
- Conditions
- Immune Thrombocytopenia
- Interventions
- First Posted Date
- 2023-12-19
- Last Posted Date
- 2023-12-26
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 132
- Registration Number
- NCT06176235
- Locations
- 🇨🇳
China-Japan Friendship Hospital, Beijing, China
🇨🇳Chinese PLA General Hospital, Beijing, China
🇨🇳Peking University Insititute of Hematology, Peking University People's Hospital, Beijing, China
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
- Conditions
- Multiple Sclerosis
- Interventions
- Drug: Placebo infusionDrug: Placebo tabletDrug: MRI contrast-enhancing agents
- First Posted Date
- 2023-11-21
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1400
- Registration Number
- NCT06141473
- Locations
- 🇮🇹
Investigational Site Number : 3800014, Chieti, Italy
🇮🇹Investigational Site Number : 3801027, Cuneo, Italy
🇮🇹Investigational Site Number : 3800020, Verona, Italy
An International, Multicenter, Randomized, Double-Blind, Double-Masked Study of the Efficacy and Safety of BCD-132 (JSC BIOCAD, Russia) Using an Active Reference Drug (Teriflunomide) for the Treatment of Patients With Multiple Sclerosis
- First Posted Date
- 2022-05-23
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Biocad
- Target Recruit Count
- 336
- Registration Number
- NCT05385744
- Locations
- 🇷🇺
State Budgetary Healthcare Institution of the Moscow Region M.F. Vladimirsky Moscow Regional Research and Clinical Institute, Moscow, Russian Federation
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- First Posted Date
- 2021-12-14
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 800
- Registration Number
- NCT05156281
- Locations
- 🇺🇸
Neurocare Plus, Houston, Texas, United States
🇺🇸Ctr for Neurology and Spine, Phoenix, Arizona, United States
🇺🇸Vladimir Royter MD APMC, Hanford, California, United States
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- First Posted Date
- 2021-12-07
- Last Posted Date
- 2025-03-03
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 800
- Registration Number
- NCT05147220
- Locations
- 🇺🇸
US Associates in Research, Miami, Florida, United States
🇺🇸AZ Integrated Neuro and Spine, Phoenix, Arizona, United States
🇺🇸Honor Health Research Institute, Scottsdale, Arizona, United States
Teriflunomide vs. Placebo During Gluten Challenge in Celiac Disease
- First Posted Date
- 2021-03-19
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Oslo University Hospital
- Target Recruit Count
- 15
- Registration Number
- NCT04806737
- Locations
- 🇳🇴
Dept of Gastroenterology, Oslo, Norway
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.